| __timestamp | Arrowhead Pharmaceuticals, Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 7461000 |
| Thursday, January 1, 2015 | 34718089 | 13047000 |
| Friday, January 1, 2016 | 40998209 | 11253000 |
| Sunday, January 1, 2017 | 32022880 | 13933000 |
| Monday, January 1, 2018 | 19110051 | 29514000 |
| Tuesday, January 1, 2019 | 26556257 | 37121000 |
| Wednesday, January 1, 2020 | 52275890 | 67929000 |
| Friday, January 1, 2021 | 80981000 | 118818000 |
| Saturday, January 1, 2022 | 124431000 | 159371000 |
| Sunday, January 1, 2023 | 90932000 | 213894000 |
| Monday, January 1, 2024 | 98761000 |
Cracking the code
In the competitive landscape of biopharmaceuticals, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have shown distinct trends in their SG&A spending from 2014 to 2023. Arrowhead's SG&A expenses grew by approximately 300% over this period, peaking in 2022. In contrast, BioCryst's expenses surged by nearly 2800%, with a significant spike in 2023. This divergence highlights differing strategic priorities and operational efficiencies. Notably, BioCryst's 2023 expenses were more than double those of Arrowhead, suggesting a more aggressive expansion or restructuring strategy. However, data for 2024 is incomplete, leaving room for speculation on future trends. As these companies navigate the evolving pharmaceutical landscape, their SG&A strategies will be pivotal in determining their competitive edge.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared